This Key Indicators report presents selected findings of the 2019 EMDHS. A comprehensive analysis of the data will be publishedin a final report in 2019.T he primary objective of the 2019 EMDHS project is to provide up-to-date estimates of key demographic and health indicators.
.This assessment was conducted using focus group discussion(FGD)with peopleliving with disabilities who were members of the Ethiopian National Association of the Deaf(Person with hearing impairment), Ethiopian National Association of the Deaf -Blind ( Person with hearing and visual impairment), Ethi...opian National Association of the Blind (Person with visual impairment), Ethiopian National Association of the Physically Handicapped (Person with physical impairment), Ethiopian National Association of Intellectual Disability (Person with intellectual disability). In total 152 people living with disabilities participated in the discussion groups.Results from the assessment were analysed based on themes and are presented by each group in the following report.
more
This Module, Count me in! Inclusive WASH in Ethiopia, was prepared by Ethiopian authors with support from The Open University UK. It was first published in June 2018. The contributors of original material are:Girma Aboma, Manager, GAA Economic Development ConsultBethel Shiferaw, SPCC Disability Incl...usion Advisor, Ethiopian Center for Disability and Development
more
The Ethiopian Hospital Services Transformation Guidelines (EHSTG) build on and expand the Ethiopian Hospital Reform Implementation Guidelines (EHRIG) and are consistent with the Health Sector Transformation Plan (HSTP). The EHSTG, which is consistent with the national focu...s on quality improvement in health care, contains a common set of guidelines to help hospital Chief Executive Officers(CEOs), managers, and clinicians (care providers) in steering the consistent implementation of these transformational systems and processes in hospitals throughout the country. The EHSTG focused on selected management and clinical functions, including new individual service specific chapters for Emergency Medical, Outpatient and Inpatient Services, Nursing and Midwifery, Maternal, Neonatal and Child Health and Teaching Hospitals’ Management. These guidelines also incorporate recent lessons from the operationalization of the EHRIG, as well as, new national initiatives such as the Guidelines for the Management of Federal Hospitals in Ethiopia, Hospital Development Army (HDA), Clean and Safe Hospital (CASH), and Auditable Pharmaceutical Transaction and Service (APTS).
II10 Pharmacy ChapterIt is expected that the guidelines will continuously evolve as new evidence emerges regarding improved hospital care and practices that are better tailored to needs and circumstances of different tiers of public hospitals. We are grateful to all partners that have participated in the production of these guidelines. Special thanks go to our colleagues at the Clinton Health Access Initiative for their substantial contributions and support throughout the development of these guidelines as well as their dedicated efforts in support of our health reform efforts in so many other capacities
more
Preferred product characteristics” (PPCs) are key tools to incentivize and guide the development of urgently needed health products. The PPC published here describes the characteristics of new types of insecticide-treated nets (ITNs) to control malaria transmission in areas with insecticide-resist...ant mosquito populations. The document was developed to address the public health need caused by the evolution and spread of insecticide resistance, particularly to pyrethroids. Such resistance threatens the effectiveness of the current standard of malaria vector control in many countries, namely pyrethroid-only long-lasting insecticidal nets (LLINs).
more
February 2021.
Improving our response to the ongoing COVID-19 pandemic in Africa requires regularly updated information, constant innovation, and considerable support towards research and development (R&D) for priorities that respond to the African realities. Shaping the research agenda and stimula...ting the generation, translation, and dissemination of valuable knowledge is one of the core functions of the African Academy of Sciences (AAS), African Centre for Disease Control (Africa CDC), and WHO-AFRO. We need answers to a list of critical research questions that respond to the current realities on the African continent to guide the COVID-19 outbreak control efforts
more
17 February 2021
During the second joint meeting of African ministers responsible for health, ICT and transport on the rollout of the Africa Against COVID-19: Saving Lives, Economies and Livelihoods campaign, a call was made to African countries to work together towards harmonizing travel entry and... exit requirements, and to increase mutual recognition and cross-border information exchange for enhanced surveillance
more
A module from the suite of health service capacity assessments in the context of the COVID-19 pandemicINTERIM GUIDANCE5 February2021
The Community needs, perceptions and demand: community assessment toolcan be used by countries to conduct a rapid pulse survey of community health needs and perceptio...ns around effective use of essential health services during the COVID-19 outbreak. The assessment helps to establish an early warning system on the need to implement coping strategies to continue to respond to communities’ health needs throughout the course of the pandemic. This assessment tool is informed by WHO and partner tools and guidance on community health needs, continuity of essential health services and readiness planning for COVID-19
more
How far apart should the doses of vaccines be? What if I miss my second dose? Can I get two doses from two different manufacturers? How was safety of vaccines ensured? WHO’s Chief Scientist, Dr Soumya Swaminathan explains in Science in 5.
19 February 2021
The overall objective of this prospective meta-analyses (PMA) is to estimate the effect of anti-IL-6 therapy compared with usual care in hospitalized patients with suspected or confirmed COVID-19. The primary comparison is of the class effect of anti-IL-6 therapies. It will also es...timate the effects of specific anti-IL-6 therapies.
more
On this page we provide an overview of excess mortality along with charts to explore the data. You can learn in more depth about different measures of excess mortality, their strengths and limitations, and their comparability across countries
Manufacturers:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) ir...respective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.
more
In: Bonk M., Ulrichs T (eds). Global Health: Das Konzept der Globalen Gesundheit. Berlin: De Gruyter, 2021, pp. 523–556
Wohlstand, Gesundheit und Gesundheitsausgaben sind eng miteinander verknüpft. Im weltweiten Durchschnitt haben alle drei seit vielen Jahren stetig zugenommen. Im Vergleich hab...en Menschen in Ländern mit höheren Einkommen eine höhere Lebenserwartung. Die höchste Krankheitslast pro Mensch tritt in Ländern mit niedrigem Einkommen auf. Den größten Anteil an der gesamten globalen Krankheitslast haben Länder mit mittlerem Einkommen, in denen rund drei Viertel der Weltbevölkerung lebt. Im Mittel sind die Gesundheitsausgaben in Ländern mit höheren Einkommen insgesamt sowie pro Kopf höher als die Gesundheitsausgaben in Ländern mit niedrigeren Einkommen.
more
This technical guidance aims to provide guidelines to laboratories and relevant stakeholders in the European Union (EU), European Economic Area (EEA) and other countries in the WHO European region in making decisions on establishing sequencing capacities and capabilities, in making decisions on whic...h technologies to use and/or in deciding on the role of sequencing for SARS-CoV-2 diagnostics, research, outbreak investigations and surveillance. It addresses the most used sequencing technologies and their applications and proposes a central standardisation process to analyse and report the findings of SARS-CoV-2 genetic characterisations.
more
Health Evidence Network synthesis report 72